Legend Biotech Corp Hits 52-Week Low Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 09 Dec 25
Source: 144
Legend Biotech Corp experienced a significant decline of 7.73%, hitting a 52-week low amidst broader market conditions.
The Nasdaq-100 and S&P 500 indices showed slight gains, indicating a disconnect between Legend Biotech's performance and the overall market trend. This decline may reflect investor concerns regarding the company's recent developments.
As Legend Biotech navigates through this challenging period, market analysts will be closely monitoring upcoming announcements and performance metrics to gauge potential recovery and investor sentiment.
Analyst Views on LEGN
Wall Street analysts forecast LEGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LEGN is 68.10 USD with a low forecast of 48.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 17.720
Low
48.00
Averages
68.10
High
90.00
Current: 17.720
Low
48.00
Averages
68.10
High
90.00
About LEGN
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
